Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia CorpfiledCriticalPharmacia Corp
Priority to CR7222ApriorityCriticalpatent/CR7222A/en
Publication of CR7222ApublicationCriticalpatent/CR7222A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Metodos novedosos y combinaciones para el tratamiento y/o profilaxis de una condicion patologica en un sujeto, en el cual los metodos comprenden la administracion de uno o mas inhibidores de la HMG CoA reductasa y uno o mas antagonistas receptores de aldosterana, y dicha combinacion comprende uno o mas inhibidores de la HMG CoA reductasa con uno o mas de dichos antagonistas receptores de aldosterana.Novel methods and combinations for the treatment and / or prophylaxis of a pathological condition in a subject, in which the methods comprise the administration of one or more HMG CoA reductase inhibitors and one or more aldosterana receptor antagonists, and said combination comprises one or more HMG CoA reductase inhibitors with one or more of said aldosterana receptor antagonists.
CR7222A2004-01-162004-01-16
COMBINATION OF AN ALDOSTERONE RECEIVER AGONIST WITH AN HMG COA REDUCTASA INHIBITOR
CR7222A
(en)
Pcsk9 antagonist comprising a cdr3 domain of the variable region of the light and heavy chain, which inhibits the cellular uptake of ldl, pharmaceutical composition comprising said antagonist, use of this, nucleotide sequence that encodes the antagonist, vector and host cell who understands it.
Compounds derived from 1 - [{pyrrolidin-3-yl} -carbonyl] -5- (piperazin-1-ylcarbonyl) -pyrrolidine, agonists of melanocortin receptors; pharmaceutical composition; Useful in the treatment of obesity, diabetes, inflammation and erectile dysfusion.